Interleukin-33 from oligodendrocytes sustains effector differentiation of tissue-resident CD8+ T cells and is a druggable target in CNS autoimmune disease
N. Fonta, N. Page, B. Klimek, M. Piccinno, G. Di Liberto, S. Lemeille, M. Kreutzfeldt, A. L. Kastner, Y. I. Ertuna, I. Vincenti, I. Wagner, D. D. Pinschewer, D. Merkler
This study identifies IL-33 from oligodendrocytes as a key regulator of self-reactive CD8+ T cell differentiation in CNS autoimmunity and shows its potential as a therapeutic target.
bioRxiv · Jul 9, 2024 · PreprintImmunology